Camptothecinisaquinolonealkaloidprecursorofirinotecan;itisoriginallyproducedbyCamptotheca.Camptothecinexhibitsanticancerchemotherapeuticactivity,inhibitingtopoisomeraseIandinducingdouble-strandedDNAbreaks.Camptothecinisextremelycytotoxicandonlyitsderivativesareclinicallyusedaschemotherapeutics.
| CasNo. | 7689-03-4 |
|---|---|
| Purity | ≥98% |
| Formula | C20H16N2O4 |
| FormulaWt. | 348.35 |
| ChemicalName | (S)-4-Ethyl-4-hydroxy-1H-pyrano[3",4":6,7]indolizino-[1,2-b]quinoline-3,14(4H,12H)-dione |
| MeltingPoint | 264-267°C(dec.) |
| Solubility | SolubleinDMSO. |
| Appearance | Paleyellowcrystallinepowder |
| StoreTemp | -20°C |
|---|---|
| ShipTemp | Ambient |
| MSDS | C0150MSDSPDF |
|---|---|
| InfoSheet | C0150InfoSheetPDF |
Rodríguez-BernaG,Mangas-SanjuánV,Gonzalez-AlvarezM,etal.Apromisingcamptothecinderivative:Semisynthesis,antitumoractivityandintestinalpermeABIlity.EurJMedChem.2014Jun25;83C:366-373.PMID:24980118.
BerniakK,RybakP,BernasT,etal.RelationshipbetweenDNAdamageresponse,initiatedbycamptothecinoroxidativestress,andDNAreplication,analyzedbyquantitative3Dimageanalysis.CytometryA.2013Jul11.[Epubaheadofprint].PMID:23846844.
RedinboMR,StewartL,KuhnP,etal.CrystalstructuresofhumantopoisomeraseIincovalentandnoncovalentcomplexeswithDNA.Science.1998Mar6;279(5356):1504-13.PMID:9488644.
